Cargando…

Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models

We previously reported that eribulin mesylate (eribulin), a tubulin‐binding drug (TBD), could remodel tumor vasculature (i.e. increase tumor vessels and perfusion) in human breast cancer xenograft models. However, the role of this vascular remodeling in antitumor effects is not fully understood. Her...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Ken, Hamamichi, Shusei, Abe, Takanori, Akagi, Tsuyoshi, Shirota, Hiroshi, Kawano, Satoshi, Asano, Makoto, Asano, Osamu, Yokoi, Akira, Matsui, Junji, Umeda, Izumi O., Fujii, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665763/ https://www.ncbi.nlm.nih.gov/pubmed/28869796 http://dx.doi.org/10.1111/cas.13392

Ejemplares similares

Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
por: Ito, Ken, et al.
Publicado: (2015)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
por: Hamamichi, Shusei, et al.
Publicado: (2021)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
por: Goto, Wataru, et al.
Publicado: (2020)

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
por: Kashiwagi, Shinichiro, et al.
Publicado: (2018)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

A landmark in drug discovery based on complex natural product synthesis
por: Kawano, Satoshi, et al.
Publicado: (2019)

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
por: Agoulnik, Sergei I, et al.
Publicado: (2014)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities
por: Hamamichi, Shusei, et al.
Publicado: (2020)

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
por: Morisaki, Tamami, et al.
Publicado: (2021)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Multivalent Carbohydrate Nanocomposites for Tumor Microenvironment Remodeling to Enhance Antitumor Immunity
por: Hyun, Gyu Hwan, et al.
Publicado: (2023)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor
por: OKAMOTO, KIYOSHI, et al.
Publicado: (2011)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
por: Watanabe, Junichiro, et al.
Publicado: (2017)

HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity
por: Nguyen, Andrew, et al.
Publicado: (2022)

Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis
por: Matsui, Koshi, et al.
Publicado: (2023)

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
por: Oba, Takaaki, et al.
Publicado: (2016)

429 Eribulin Synergizes with STING Agonists by Enhancing Type 1 Interferon Expression and Improves Antitumor Efficacy as Combination Treatment
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2023)

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
por: Nakagawa, Takayuki, et al.
Publicado: (2014)

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1dvo0fbo45jteltjnbrdfuh9dd